AEterna Zentaris (AEterna Zentaris) FCF Yield % : -180.77 (As of May. 01, 2024)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, AEterna Zentaris's Trailing 12-Month Free Cash Flow is $-17.14 Mil, and Market Cap is $9.24 Mil. Therefore, AEterna Zentaris's FCF Yield % for today is -180.77%.

The historical rank and industry rank for AEterna Zentaris's FCF Yield % or its related term are showing as below:

AEZS' s FCF Yield % Range Over the Past 10 Years
Min: -455.74 Med: -67.71 Max: 21.72
Current: -180.77

During the past 13 years, the highest FCF Yield % of AEterna Zentaris was 21.72%. The lowest was -455.74%. And the median was -67.71%.

AEZS's FCF Yield % is ranked worse than
90.65% of 1551 companies
in the Biotechnology industry
Industry Median: -15.06 vs AEZS: -180.77

AEterna Zentaris's FCF Margin % for the quarter that ended in Dec. 2023 was -4,450.41%.

AEterna Zentaris FCF Yield % Historical Data

The historical data trend for AEterna Zentaris's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris FCF Yield % Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-58.94

-15.48

-21.38

-88.66

-189.74

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-87.50	-127.74	-137.43	-111.80	-238.49

Competitive Comparison of AEterna Zentaris's FCF Yield %

For the Biotechnology subindustry, AEterna Zentaris's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's FCF Yield % distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's FCF Yield % falls into.

AEterna Zentaris FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

AEterna Zentaris's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-17.137	/	9.0319368
	=	-189.74%

AEterna Zentaris's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-5.385	*	4	/	9.0319368
	=	-238.49%

AEterna Zentaris FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

AEterna Zentaris FCF Yield % Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.